Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World September 26, 2014 Rebecca Trager	Merck KGaA to buy Sigma--Aldrich German chemicals conglomerate Merck KGaA has agreed to buy US specialty chemicals company Sigma -- Aldrich for $17 billion
The Motley Fool February 26, 2009 Robert Steyer	Merck KGaA's Good Chemistry This German conglomerate successfully mixes drugs and chemicals.
Chemistry World August 24, 2012 Andrew Turley	Merck KGaA buys cell culture company Merck KGaA has struck a deal to buy German company Biochrom, which makes cell culture media and buffer solutions, for an undisclosed price.
Chemistry World February 19, 2013 Andrew Turley	Merck resolves Vytorin case for $688m Merck & Co has agreed to pay $688 million to settle claims that it failed to report clinical trial data relating to cholesterol brands Zocor (simvastatin) and Vytorin (ezetimibe, simvastatin).
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull Rebuttal Plenty of cash. Big pipeline. Not to worry. The future can't be predicted, but Merck's history shows its ability to weather even the toughest pharmaceutical-development environments.
Chemistry World September 6, 2012 Andrew Turley	Merck KGaA to cut 1100 German jobs Merck KGaA has announced plans to cut 1100 jobs in Germany -- a 10% reduction in its German workforce. The job cuts will be made by the end of 2015, 'in a socially acceptable manner.
The Motley Fool September 1, 2009 Brian Orelli	Merck to Bride: Leave the Jewelry at Home The new Merck will look a lot like the old Merck at the top, even though about 40% of Schering's senior leaders will be headed to the new company.
The Motley Fool November 29, 2010 Brian Orelli	There's Still Only One Merck KGaA's oral MS drug delay is Novartis' gain.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull It's hard to argue with a price this cheap. With a price-to-free cash flow ratio of less than 11, Merck's a steal.
Chemistry World May 19, 2014 Phillip Broadwith	AstraZeneca refuses Pfizer's 'final' offer The US giant has described this proposal, valuing AZ at 70 billion pounds, as 'final' and says it 'cannot be increased'.
The Motley Fool October 23, 2007 Brian Orelli	Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter.
The Motley Fool September 29, 2006 Brian Lawler	Merck Likes FoxHollow The pharmaceutical giant signs another collaborative research agreement with the small-cap company. Investors, take note.
The Motley Fool February 8, 2008 Brian Orelli	Merck in Lukewarm Water The pharmaceutical's settlement ends a government probe into Medicaid overcharging allegations.
Chemistry World October 9, 2013	Solvay expands surfactants business with Chemlogics buyout Speciality chemicals group Solvay has agreed to buy Chemlogics -- a US firm specializing in chemicals for oil and gas exploration -- for $1.3 billion ( 840 million) in cash.
The Motley Fool May 6, 2008 Brian Orelli	A Sign of the Pharma Times Merck is the latest big pharma cutting jobs to improve its bottom line.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull Rebuttal Priced at a P/E of 13 and paying you a 4.8% dividend, Merck isn't just affordable -- it's a stock you can't afford not to own.
The Motley Fool October 21, 2004 Brian Gorman	Merck Is Down But Not Out The pharma's woes may have silver linings. For now, the company's investors might want to sit tight.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
The Motley Fool December 21, 2006 Brian Lawler	Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout.
The Motley Fool October 22, 2008 Brian Orelli	Merck's a Bloated Garbage Heap of Stale Drugs Now Merck is planning on cutting 12% of its workforce in the hopes of saving $4 billion through 2013.
The Motley Fool May 21, 2008 Brian Orelli	OK, Last Vioxx Settlement, Honest! What's another $58 million when Merck's already forking over $4.85 billion?
The Motley Fool November 30, 2004 Rich Smith	Merck Execs Circle the Wagons Shareholder anger is elicited by a filing that Merck made with the Securities and Exchange Commission, announcing that in anticipation of a possible hostile takeover, its executives are taking all possible measures to protect... themselves.
The Motley Fool July 23, 2007 Brian Lawler	Merck Not Hurt Merck repeats another nice quarter of bottom-line growth despite growing concerns about generic competition.
Chemistry World June 19, 2013 Laura Howes	AstraZeneca announce new UK hub The new hub will consolidate all of AZ's UK activities, including biologics arm MedImmune, at the Cambridge Biomedical Campus on the southern outskirts of the city.
The Motley Fool December 29, 2006 Brian Lawler	Sirna Decides to Take the Cash and Run Shareholders vote to approve Merck's buyout offer. Investors in shares of Merck really have to trust management to have done its due diligence on Sirna and to have faith in its technology.
Chemistry World March 2, 2015 Phillip Broadwith	AstraZeneca to spin off anti-infectives research The new company's principal asset will be the novel gyrase inhibitor AZD0914, which is currently in Phase II clinical trials for treating gonorrhea.
The Motley Fool March 18, 2009 Brian Orelli	Merck Pummels Pfizer One of these acquisitions is not like the other.
The Motley Fool July 8, 2010 Brian Orelli	Surprise Us in a Good Way, Merck Keeping up productivity during plant closures won't be easy.
The Motley Fool August 30, 2010 Brian Orelli	It's a Blockbuster ... Maybe On the surface, sanofi-aventis' oral multiple sclerosis drug teriflunomide looks like a hit. But below the surface?
Chemistry World October 23, 2008 Matt Wilkinson	Merck to slash more jobs Beleaguered US pharma giant, Merck & Co., has announced new restructuring plans that will see the company cut 7,200 jobs in an effort to save up to $4.2 billion
The Motley Fool January 31, 2005 Stephen D. Simpson	Merck Takes Another Body Blow Loss of exclusivity on major osteoporosis drug could take steam out of the recovery process. Investors in Merck just can't catch a break.
The Motley Fool January 31, 2007 Brian Lawler	Merck Plays the Waiting Game New acquisitions may help the drugmaker weather tough times. Investors, take note.
The Motley Fool April 17, 2007 Brian Lawler	Merck Raises the Earnings Roof Shares of Merck soar after it raises 2007 earnings guidance.
Chemistry World November 9, 2015 Phillip Broadwith	AstraZeneca to buy ZS Pharma for ion-balance drugs AstraZeneca has agreed to buy US specialist drug company ZS Pharma for around $2.7 billion in an effort to bolster its drug pipeline.
The Motley Fool February 21, 2006 Rick Aristotle Munarriz	Biggest Disappointment: Merck In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: Merck is rich in cash, tradition, and potholes.
The Motley Fool November 5, 2007 Brian Orelli	Last Look at Mini-Mylan An impending merger with Merck's KGaA's generic drug business should more than double revenue at Mylan.
The Motley Fool June 30, 2008 Brian Orelli	A Drug to End Merck's Headache? Merck presents promising data for its phase 3 migraine drug.
The Motley Fool January 25, 2005 Stephen D. Simpson	Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today.
Chemistry World January 11, 2010 Sean Milmo	Evonik refocuses German chemicals, energy and real estate conglomerate Evonik Industries, is refocusing its operations on its chemical business in order to become a more powerful global player in the speciality chemicals arena.
The Motley Fool July 21, 2009 Brian Orelli	Merck and Schering: A Less Ugly Bride and Groom Merck and Schering-Plough are up today on "better than expected" earnings, but the bride and groom don't look all that great heading into the wedding.
The Motley Fool March 2, 2005 Brant David McLaughlin	Merck's Road to Recovery Merck didn't get to where it is by being shortsighted, and management has no plans to start now. Investors would be wise not to take on an excessively negative attitude toward the company in the wake of some dark news.
The Motley Fool January 27, 2004 Jeff Hwang	Merck in the Balance These are troubled times for Merck. Restructuring charges, Zocor sales woes, and a new distribution program hamper earnings.
The Motley Fool October 23, 2006 Brian Lawler	Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount.
Chemistry World June 12, 2014 Philli Broadwith	Merck & Co bolsters hepatitis C pipeline with Idenix acquisition US drug firm Merck & Co has agreed to buy hepatitis C specialist Idenix for $3.85 billion.
The Motley Fool November 5, 2009 Brian Orelli	Slow Down There, Merck Merck CEO Richard Clark says his company is looking to do more deals than ever, perhaps "even try to double" the current rate of 50 per year.
The Motley Fool August 26, 2005 Stephen D. Simpson	Merck Broaches the Obvious Merck will naturally end up settling many Vioxx cases, but the details are far from clear at this point. Investors, take note.
Pharmaceutical Executive January 1, 2006 Jeannette Park	Thought Leader: Q&A with Cheryl Buxton Cheryl Buxton talks about what impact Merck's decision to cut nearly 11 percent of its work force - in hopes of saving $4 billion dollars by 2010 - will have on the company's future.
Chemistry World May 28, 2014 Phillip Broadwith	Time called on Pfizer -- AstraZeneca deal Pfizer's pursuit of a pharmaceutical megamerger has concluded with the US giant withdrawing its final offer two hours before the deadline set by the UK's takeover rules.
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool February 24, 2011 Jordan DiPietro	Should You Retire With Merck? Is Merck a good choice for a retirement portfolio?